Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29106380 | 0.98 | GLS (0.33) | GLSTRPV3NOTUMPSMB8PSMB9 | |
| SCHEMBL10065478 | 0.79 | KDM4E (0.40) | HTR2CSLC6A4 | |
| SCHEMBL15728774 | 0.79 | NOTUM (0.34) | GLSNOTUMPSMB8PSMB9PSMB5 | |
| SCHEMBL23757322 | 0.73 | PSMB8 (0.33) | TRPV3PSMB8PSMB9PSMB5 | |
| SCHEMBL23757325 | 0.73 | PSMB8 (0.33) | TRPV3PSMB8PSMB9PSMB5 | |
| SCHEMBL24468102 | 0.73 | MBOAT4 (0.43) | — | |
| SCHEMBL27284070 | 0.72 | GLS (0.48) | GLSTRPV3NOTUMPSMB8PSMB9 | |
| SCHEMBL21017387 | 0.71 | GLS (0.46) | GLSNOTUMPSMB8PSMB9PSMB5 | |
| SCHEMBL10619802 | 0.69 | CTSK (0.38) | GLSTRPV3 | |
| SCHEMBL10619810 | 0.69 | CTSK (0.38) | GLSTRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116783191-A | Tricyclic carboxamide derivatives as PRMT5 inhibitors | 美国安进公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | GLS 184/4885TRPV3 4385/4885NOTUM 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.